David Alleva

David Alleva boasts over 2 decades of experience in the biopharma industry and academic research, specializing in small-molecule, vaccine, and antibody therapeutic efforts for Immunology and Inflammation-based treatments. Currently, he is actively involved in providing scientific and business expertise to various startup biotech firms focused on drug discovery and development, particularly in immunology and inflammation-based therapeutics geared towards autoimmune diseases like Type 1 Diabetes. His broad network of professional relationships enables him to assemble talented individuals to tackle challenges and create opportunities for success. David excels in developing value propositions, therapeutic development plans, and business strategies that are attractive to investors. His grant writing skills have been instrumental in securing non-dilutive financing through sources like NIH SBIR and foundation grants.